Exclusive: Global trial finds treatment with amivantamab and lazertinib halts progression for average of 23.7 months
Source: ‘Amazing’ trial shows drug combination stops lung cancer advancing for longer
Wow!
A Daily Antidote to Everything Else
Exclusive: Global trial finds treatment with amivantamab and lazertinib halts progression for average of 23.7 months
Source: ‘Amazing’ trial shows drug combination stops lung cancer advancing for longer
Wow!